84 related articles for article (PubMed ID: 21391426)
1. Ten-month laryngeal allograft survival with use of pulsed everolimus and anti-alphabeta T-cell receptor antibody immunosuppression.
Lott DG; Russell JO; Khariwala SS; Dan O; Strome M
Ann Otol Rhinol Laryngol; 2011 Feb; 120(2):131-6. PubMed ID: 21391426
[TBL] [Abstract][Full Text] [Related]
2. Pulsed immunosuppression with everolimus and anti-alphabeta T-cell receptor: laryngeal allograft preservation at six months.
Khariwala SS; Knott PD; Dan O; Klimczak A; Siemionow M; Strome M
Ann Otol Rhinol Laryngol; 2006 Jan; 115(1):74-80. PubMed ID: 16466103
[TBL] [Abstract][Full Text] [Related]
3. Long-term laryngeal allograft survival using low-dose everolimus.
Lott DG; Dan O; Lu L; Strome M
Otolaryngol Head Neck Surg; 2010 Jan; 142(1):72-8. PubMed ID: 20096226
[TBL] [Abstract][Full Text] [Related]
4. Donor bone marrow in laryngeal transplantation: results of a rat study.
Khariwala SS; Dan O; Lorenz RR; Klimczak A; Siemionow M; Strome M
Am J Otolaryngol; 2008; 29(4):242-9. PubMed ID: 18598835
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of parathyroid hormone as a functional biological marker of rat laryngeal transplant rejection.
Nelson M; Dan O; Strome M
Laryngoscope; 2003 Sep; 113(9):1483-6. PubMed ID: 12972920
[TBL] [Abstract][Full Text] [Related]
6. Laryngeal transplantation in the setting of cancer: a rat model.
Shipchandler TZ; Lorenz RR; Lee WT; Teker AM; Dan O; Strome M
Laryngoscope; 2008 Dec; 118(12):2166-71. PubMed ID: 18948827
[TBL] [Abstract][Full Text] [Related]
7. Donor-specific tolerance in fully major histocompatibility major histocompatibility complex-mismatched limb allograft transplants under an anti-alphabeta T-cell receptor monoclonal antibody and cyclosporine A protocol.
Siemionow MZ; Izycki DM; Zielinski M
Transplantation; 2003 Dec; 76(12):1662-8. PubMed ID: 14688512
[TBL] [Abstract][Full Text] [Related]
8. Induction of tolerance in a rat model of laryngeal transplantation.
Akst LM; Siemionow M; Dan O; Izycki D; Strome M
Transplantation; 2003 Dec; 76(12):1763-70. PubMed ID: 14688529
[TBL] [Abstract][Full Text] [Related]
9. Induction with T-cell receptor antibody leads to long-term laryngeal allograft function.
Knott PD; Dan O; Strome M
Am J Otolaryngol; 2008; 29(6):398-402. PubMed ID: 19144301
[TBL] [Abstract][Full Text] [Related]
10. Prolongation of corneal allograft survival by topical application of everolimus in experimental keratoplasty.
Li XQ; Buch G; Otasevic L; Schlickeiser S; Bertelmann E; Pleyer U
Ophthalmic Res; 2008 Oct; 40(6):309-14. PubMed ID: 18688173
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival of limb allografts induced by pharmacologically conditioned, donor alloantigen-pulsed dendritic cells without maintenance immunosuppression.
Ikeguchi R; Sacks JM; Unadkat JV; Solari M; Horibe EK; Thomson AW; Lee AW; Feili-Hariri M
Transplantation; 2008 Jan; 85(2):237-46. PubMed ID: 18212629
[TBL] [Abstract][Full Text] [Related]
12. Alloantigen-pulsed host dendritic cells induce T-cell regulation and prolong allograft survival in a rat model of hindlimb allotransplantation.
Kuo YR; Huang CW; Goto S; Wang CT; Hsu LW; Lin YC; Yang KD; Chen CL; Lee WP
J Surg Res; 2009 May; 153(2):317-25. PubMed ID: 19101689
[TBL] [Abstract][Full Text] [Related]
13. Anti-αβ-T-cell receptor antibodies in the setting of laryngeal transplantation.
Strome M; Lott DG
Immunotherapy; 2010 Nov; 2(6):835-45. PubMed ID: 21091115
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus and mycophenolate mofetil provide effective immunosuppression in rat laryngeal transplantation.
Nelson M; Fritz M; Dan O; Worley S; Strome M
Laryngoscope; 2003 Aug; 113(8):1308-13. PubMed ID: 12897551
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates.
Machka C; Lange S; Werner J; Wacke R; Killian D; Knueppel A; Knuebel G; Vogel H; Lindner I; Roolf C; Murua Escobar H; Junghanss C
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1301-6. PubMed ID: 24923538
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.
Majewski M; Korecka M; Joergensen J; Fields L; Kossev P; Schuler W; Shaw L; Wasik MA
Transplantation; 2003 May; 75(10):1710-7. PubMed ID: 12777861
[TBL] [Abstract][Full Text] [Related]
17. Effect of in vitro irradiation of donor larynges on cyclosporine requirements and rejection rates in rat laryngeal transplantation.
Barthel SW; Dan O; Myles J; Strome M
Ann Otol Rhinol Laryngol; 2001 Jan; 110(1):20-4. PubMed ID: 11201803
[TBL] [Abstract][Full Text] [Related]
18. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
19. Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study.
Spagnoletti G; Favi E; Gargiulo A; Salerno MP; Citterio F
Transplant Proc; 2011 May; 43(4):1010-2. PubMed ID: 21620038
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the immunosuppressive regimen in heart transplantation.
Eisen H; Ross H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
